BIOVICA INTERNATIONAL AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.73 SEK | +0.58% |
|
+13.82% | -32.95% |
| Apr. 13 | Certain B Shares of Biovica International AB are subject to a Lock-Up Agreement Ending on 13-APR-2024. | CI |
| Apr. 12 | Biovica International AB Announces Divitum® Tka in Observational Trial | CI |
Valuation
| Fiscal Period: April | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 204.7 | 369.2 | 1,157 | 905.9 | 331.2 | 145.4 | - | - |
| Enterprise Value (EV) 1 | 187.9 | 328.4 | 1,012 | 829.4 | 331.2 | 71.89 | 99.47 | 134.1 |
| P/E ratio | -8.98 x | -12 x | -29.3 x | -15.1 x | -2.28 x | -0.23 x | -0.6 x | 2.18 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 68.1 x | 221 x | 557 x | 443 x | 97.9 x | 14.5 x | 1.25 x | 0.57 x |
| EV / Revenue | 62.5 x | 197 x | 487 x | 406 x | 97.9 x | 7.19 x | 0.86 x | 0.52 x |
| EV / EBITDA | -10 x | -12.8 x | -29.7 x | -15.5 x | -3.24 x | -0.68 x | -1.84 x | -24.1 x |
| EV / FCF | -7.43 x | -10.3 x | -26.7 x | -15 x | - | -0.65 x | -1.78 x | 6.7 x |
| FCF Yield | -13.5% | -9.69% | -3.75% | -6.65% | - | -153% | -56.3% | 14.9% |
| Price to Book | 3.73 x | - | 6.33 x | 7.29 x | - | 1.43 x | 2.36 x | 5.41 x |
| Nbr of stocks (in thousands) | 18,527 | 23,817 | 28,418 | 28,488 | 45,741 | 84,056 | - | - |
| Reference price 2 | 11.05 | 15.50 | 40.70 | 31.80 | 7.240 | 1.730 | 1.730 | 1.730 |
| Announcement Date | 6/14/19 | 6/5/20 | 6/17/21 | 6/16/22 | 6/21/23 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: April | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3.005 | 1.671 | 2.077 | 2.045 | 3.383 | 10 | 116 | 256 |
| EBITDA 1 | -18.7 | -25.65 | -34.04 | -53.66 | -102.2 | -106.4 | -54.07 | -5.556 |
| EBIT 1 | -21.72 | -29.82 | -40.18 | -60.1 | -110.5 | -115.6 | -63.77 | -15.25 |
| Operating Margin | -722.73% | -1,784.32% | -1,934.57% | -2,938.92% | -3,265.06% | -1,155.98% | -54.98% | -5.96% |
| Earnings before Tax (EBT) 1 | -21.52 | -30.26 | -39.39 | -59.99 | -110.7 | -113.3 | -62.51 | -41.88 |
| Net income 1 | -21.56 | -30.32 | -39.48 | -60 | -110.5 | -114.8 | -60.01 | -41.88 |
| Net margin | -717.34% | -1,814.36% | -1,900.91% | -2,934.13% | -3,266.1% | -1,148.09% | -51.73% | -16.36% |
| EPS 2 | -1.230 | -1.290 | -1.390 | -2.110 | -3.180 | -7.422 | -2.866 | 0.7936 |
| Free Cash Flow 1 | -25.3 | -31.82 | -37.97 | -55.12 | - | -110 | -56 | 20 |
| FCF margin | -841.8% | -1,903.95% | -1,828.07% | -2,695.21% | - | -1,100% | -48.28% | 7.81% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 6/14/19 | 6/5/20 | 6/17/21 | 6/16/22 | 6/21/23 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: April | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 1.082 | - | - | 0.587 | 1.754 | 2.563 | 1.075 | 5 | - | - | - | - |
| EBITDA 1 | -13.24 | -12.89 | -17.32 | - | -27.24 | -35.2 | -29.84 | -22.92 | -25.53 | -27.75 | -17 | -17 | -17 | -13 |
| EBIT 1 | -14.48 | -14.42 | -19.13 | - | -29.28 | -37.21 | -32.19 | -25.32 | -27.85 | -30.42 | -19 | -19 | -19 | -16 |
| Operating Margin | - | - | -1,768.21% | - | - | -6,338.67% | -1,835.35% | -987.75% | -2,590.51% | -608.44% | - | - | - | - |
| Earnings before Tax (EBT) 1 | -14.49 | -14.33 | -19.07 | - | -29.18 | -37.2 | -31.94 | -23.77 | -27.58 | -34.33 | -18.63 | -18.53 | -18.92 | -14.94 |
| Net income 1 | -14.49 | -14.33 | -19.06 | -23.25 | -28.54 | -37.7 | -32.26 | -25.68 | -27.34 | -34.33 | -18.63 | -18.53 | -18.92 | -14.94 |
| Net margin | - | - | -1,761.18% | - | - | -6,422.49% | -1,839.45% | -1,002.11% | -2,543.53% | -686.58% | - | - | - | - |
| EPS 2 | -0.5100 | -0.5000 | -0.6700 | -0.8100 | -0.6400 | -0.8100 | -0.7000 | -0.5600 | -0.4400 | -0.4042 | -0.2216 | -0.1997 | -0.1865 | -0.1472 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 12/1/21 | 3/15/22 | 6/16/22 | 12/15/22 | 3/16/23 | 6/21/23 | 9/6/23 | 11/28/23 | 3/14/24 | - | - | - | - | - |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: April | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 16.8 | 40.8 | 144 | 76.5 | - | 73.5 | 45.9 | 11.3 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -25.3 | -31.8 | -38 | -55.1 | - | -110 | -56 | 20 |
| ROE (net income / shareholders' equity) | -34.3% | - | -30.3% | -39.1% | - | -91% | -46% | 14% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 2.960 | - | 6.430 | 4.360 | - | 1.210 | 0.7300 | 0.3200 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 7.33 | 7.04 | 3.56 | 2.99 | - | - | 1 | 1 |
| Capex / Sales | 243.89% | 421.01% | 171.4% | 146.31% | - | - | 0.86% | 0.39% |
| Announcement Date | 6/14/19 | 6/5/20 | 6/17/21 | 6/16/22 | 6/21/23 | - | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.73
SEK
Average target price
9.9
SEK
Spread / Average Target
+472.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -32.95% | 13.51M | |
| -27.70% | 9.88B | |
| +27.06% | 2.89B | |
| -16.78% | 2.88B | |
| -15.31% | 2.12B | |
| -21.41% | 1.67B | |
| +68.70% | 1.45B | |
| +29.75% | 788M | |
| -5.02% | 741M | |
| -29.39% | 514M |
- Stock Market
- Equities
- BIOVIC B Stock
- Financials Biovica International AB
